U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717411) titled 'A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease' on July 17.
Brief Summary: This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Study Start Date: Nov. 30, 2026
Study Type: INTERVENTIONAL
Condition:
Alzheimer's Disease
Intervention:
DRUG: Trontinemab
Participants will receive IV trontinemab.
DRUG: Placebo
Participants wi...